Advertisement

Topics

FDA expands use of AstraZeneca/Merck ovarian cancer drug

13:24 EDT 17 Aug 2017 | Reuters

(Reuters) - The U.S. Food and Drug Administration on Thursday expanded the use of Lynparza, sold by AstraZeneca Plc and Merck & Co Inc, to include ongoing treatment of patients with recurrent ovarian cancer who have responded to platinum-based chemot...

Original Article: FDA expands use of AstraZeneca/Merck ovarian cancer drug

NEXT ARTICLE

More From BioPortfolio on "FDA expands use of AstraZeneca/Merck ovarian cancer drug"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

AstraZeneca
AstraZeneca is ranked 6th in the world, based on a pharmaceutical annual sales, which were valued at $32,800 million in 2009.  it is a global company, working in more than 100 countries, and employing 62,000 people, around a sixth of which are dedic...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...